Drug Action
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Source page 754
Loading InternPractice…
Individual generic drug information
Extracted information for Saxagliptin only.
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Source page 754
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic control ▶BY MOUTH ▶Adult: 5 mg once daily, for further information on use with other antidiabetic drugs—consult product literature
Source page 754
DUE TO INTERACTIONS ▶Dose of concomitant sulfonylurea or insulin may need to be reduced.
Source page 754
Elderly. history of pancreatitis. moderate to severe heart failure (limited experience)
Source page 754
Contra-indicated if patient has a history of serious hypersensitivity to dipeptidylpeptidase-4 inhibitors.
Source page 755
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised that saxagliptin (Onglyza ®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).
Source page 755
Extracted information for Saxagliptin only.
→Appendix 1: saxagliptin
Source page 754
▶Common or very common Abdominal pain. dizziness. fatigue. headache. increased risk of infection. skin reactions. vomiting ▶Uncommon Pancreatitis ▶Rare or very rare Angioedema ▶Frequency not known Constipation. nausea SIDE-EFFECTS, FURTHER INFORMATION Discontinue if symptoms of acute pancreatitis occur such as persistent, severe abdominal pain.
Source page 754
Avoid unless essential—toxicity in animal studies.
Source page 755
Avoid—present in milk in animal studies.
Source page 755
Manufacturer advises caution in moderate impairment; avoid in severe impairment (risk of increased exposure).
Source page 755
Use with caution in severe impairment. Dose adjustments Reduce dose to 2.5 mg once daily in moderate to severe impairment.
Source page 755
Determine renal function before treatment and periodically thereafter.
Source page 755
Extracted information for Saxagliptin only.
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Onglyza (AstraZeneca UK Ltd) Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg Onglyza 2.5mg tablets | 28 tablet P £31.60 DT = £31.60 Saxagliptin (as Saxagliptin hydrochloride) 5 mg Onglyza 5mg tablets | 28 tablet P £31.60 DT = £31.60
Source page 755
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
5 mg once daily, for further information on use
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 754